Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

Leah Andrews(University of Washington), María L. Alcaide, Lilly Cheng Immergluck, Nina Ahmad, Hong‐Van Tieu(New York Blood Center), M. Elizabeth Halloran(University of Washington), Ronald Ackerman, Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Brendan Flannery(Centers for Disease Control and Prevention), Michael Adams, Thomas Campbell(University of Colorado Anschutz Medical Campus), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Getahun Abate(Saint Louis University), Leigh H. Fisher(Fred Hutch Cancer Center), Guy de Bruyn(University of Namur), Nadine Rouphael(Emory University), Lars van der Laan(University of Washington), Hana M. El Sahly(Baylor College of Medicine), Frances Priddy(International AIDS Vaccine Initiative), Holly Janes(Fred Hutch Cancer Center), Julie A. Ake(Walter Reed Army Institute of Research), Christine Akamine, Dean Follmann(National Institute of Allergy and Infectious Diseases), Jeremy Ackermann, Jessica Andriesen(Adaptive Biotechnologies (United States)), Sarah Afework, Kelsey M. Sumner(Centers for Disease Control and Prevention), Mayur Patel(Fred Hutch Cancer Center), Jamie Ackerman, Mark Adams, Carla Truyers(University of Maryland, Baltimore), Jeffrey Adelglass, Colleen F. Kelley(Emory University), Benjamin J. Luft(Stony Brook School), Anum Abbas, Deborah Theodore(Columbia University), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Magdalena E. Sobieszczyk(Columbia University Irving Medical Center), Ann R. Falsey(University of Rochester), Gary Albert, Lindsey R. Baden(Brigham and Women's Hospital), Karina Abalos, Michael R. Adams(Launchpad Central (United States)), Catherine Healy(Baylor College of Medicine), José Accini, Atoya Adams, Vanessa Abad, Ian Hirsch(AstraZeneca (United Kingdom))
JAMA Network Open
May 28, 2025
Cited by 6


Related Papers